サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1452585

アジア太平洋のグリオーマ治療：2030年までの市場予測 - 地域別分析 - 疾患別、治療タイプ別、グレード別、エンドユーザー別

Asia Pacific Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User
出版日: | 発行: The Insight Partners | ページ情報: 英文 97 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
アジア太平洋のグリオーマ治療：2030年までの市場予測 - 地域別分析 - 疾患別、治療タイプ別、グレード別、エンドユーザー別
出版日: 2024年01月15日
発行: The Insight Partners
ページ情報: 英文 97 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アジア太平洋のグリオーマ治療市場は、2022年の7億5,497万米ドルから2030年には15億3,888万米ドルに成長すると予測されています。2022年から2030年までのCAGRは9.3%と推定されます。

新興経済圏での機会増加がアジア太平洋のグリオーマ治療市場を後押し

ブラジル、ロシア、インド、中国、南アフリカ（BRICS）は、世界で最も急成長している経済圏のひとつです。これらの国々やその他の新興経済諸国の医療分野は、今後数年間で急速に拡大すると予測されています。期待される成長の背景には、顧客需要の変化、ヘルスケアサービスに対する意識の高まり、高齢化人口の継続的な増加があります。脳腫瘍診断薬の世界市場は、ヘルスケア分野の普及に伴い、今後数年間で大きく成長する可能性が高いです。さらに、医療施設に対する政府支出の増加と消費者の購買力が、新興諸国におけるヘルスケア部門の成長に寄与しています。

アジア諸国は、進行中の臨床研究、一元化された医療機関、優秀で意欲的な労働力、優れた臨床試験施設により、科学的能力が継続的に成長しています。さらに、アジア太平洋の多くの国々には、世界人口の約60％が居住する、大規模で多様な患者層が存在します。米国やEUの規制機関が作成した治療ガイドラインは、アジア太平洋の疾患治療にも適用されており、患者募集が迅速かつ大幅に行われる見込みがあります。このように、アジア太平洋の新興諸国におけるヘルスケアセクターの成長は、アジア太平洋のグリオーマ治療市場のプレーヤーが事業を拡大するためのより良い機会を生み出しています。

アジア太平洋のグリオーマ治療市場の概要

アジア太平洋のグリオーマ治療市場は、予測期間中に最も速いCAGRで成長することが期待されています。中国、インド、日本は、この地域の市場成長に貢献する3つの主要な要因です。同市場は主に、各国の政府および民間部門による投資の増加によって牽引されています。治療開発のためのアジア諸国と新興諸国との協力関係の増加、脳腫瘍治療に対する需要の増加、脳腫瘍の有病率の上昇は、予測期間中にアジア太平洋のグリオーマ治療市場を牽引すると思われる主な要因のいくつかです。

中国は人口が多く、ヘルスケアのインフラが整備されています。社会的・経済的発展の程度は沿岸部と農村部で異なります。沿岸部では、西部の農村部に比べてヘルスケア資源が比較的発達しており、容易に利用できます。他の先進国や発展途上国と同様、日本もまた、ヘルスケア・システムを強化し、国民により良い医療システムへのアクセスを提供することに注力しています。政府は様々なプログラムや研究機関を通じてゲノム検査の進歩を奨励しています。さらに、高齢者人口の増加と脳腫瘍の急増は、アジア太平洋のグリオーマ治療市場の開拓に貢献すると期待されています。

アジア太平洋のグリオーマ治療市場の収益と2030年までの予測（金額）

アジア太平洋のグリオーマ治療市場のセグメンテーション

アジア太平洋のグリオーマ治療市場は、疾患、治療タイプ、グレード、エンドユーザー、および国にセグメント化されます。

疾患に基づき、アジア太平洋のグリオーマ治療市場は星細胞腫、乏突起星細胞腫、乏突起膠腫にセグメント化されます。2022年のアジア太平洋のグリオーマ治療市場では、星細胞腫セグメントが最大のシェアを占めています。

治療タイプに基づき、アジア太平洋のグリオーマ治療市場は手術、化学療法、放射線療法、その他に区分されます。2022年のアジア太平洋のグリオーマ治療市場で最大のシェアを占めたのは手術セグメントでした。

悪性度に基づき、アジア太平洋のグリオーマ治療市場は低悪性度と高悪性度に区分されます。高悪性度セグメントは、2022年のアジア太平洋のグリオーマ治療市場でより大きなシェアを占めました。

エンドユーザー別では、アジア太平洋のグリオーマ治療市場は病院＆クリニックと外来手術センターに区分されます。2022年のアジア太平洋のグリオーマ治療市場では、病院＆クリニック市場が大きなシェアを占めています。

国別では、アジア太平洋のグリオーマ治療市場は中国、日本、インド、韓国、オーストラリア、その他アジア太平洋に区分されます。中国は、2022年のアジア太平洋のグリオーマ治療市場を独占しました。

Amgen Inc、Amneal Pharmaceuticals Inc、Biocon Ltd、F. Hoffmann-La Roche Ltd、Merck &Co Inc、Pfizer Inc、Sun Pharmaceutical Industries Ltd、Teva Pharmaceutical Industries Ltdは、アジア太平洋のグリオーマ治療市場で事業を展開している大手企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 アジア太平洋のグリオーマ治療市場- 主要産業力学

  • 市場促進要因
    • グリオーマ治療に対する政府の資金援助
    • 高悪性度グリオーマの有病率の増加
  • 主な市場抑制要因
    • 診断コストの高さ
  • 主な市場機会
    • 新興国におけるヘルスケア分野の進歩
  • 今後の動向
    • グリオーマ治療薬の承認急増
  • 影響分析

第5章 グリオーマ治療市場：アジア太平洋市場分析

  • アジア太平洋のグリオーマ治療市場の収益、2022年～2030年

第6章 アジア太平洋のグリオーマ治療市場：収益と2030年までの予測 - 疾患別

  • 市場収益シェア（%）、2022年および2030年
  • 星細胞腫
  • 乏突起星細胞腫
  • 乏突起膠腫

第7章 アジア太平洋のグリオーマ治療市場：収益と2030年までの予測 - 治療タイプ別

  • 市場収益シェア（%）、2022年および2030年
  • 手術療法
  • 化学療法
  • 放射線療法
  • その他

第8章 アジア太平洋のグリオーマ治療市場：収益と2030年までの予測 - グレード別

  • 市場収益シェア（%）、2022年および2030年
  • 低悪性度
  • 高悪性度

第9章 アジア太平洋のグリオーマ治療市場：収益と2030年までの予測 - エンドユーザー別

  • 市場収益シェア（%）、2022年および2030年
  • 病院・診療所
  • 外来手術センター

第10章 アジア太平洋のグリオーマ治療市場：国別分析

  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • その他アジア太平洋

第11章 アジア太平洋のグリオーマ治療市場：業界情勢

  • 市場参入企業の成長戦略（%）
  • 有機的展開
  • 無機的展開

第12章 企業プロファイル

  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Sun Pharmaceutical Industries Ltd
  • Amgen Inc
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Amneal Pharmaceuticals Inc
  • Biocon Ltd

第13章 付録

図表

List Of Tables

  • Table 1. Asia Pacific Glioma Treatment Market Segmentation
  • Table 2. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 3. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 4. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 5. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 6. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 7. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 8. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 9. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 10. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 11. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 12. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 13. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 14. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 15. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 16. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 17. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 18. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 19. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 20. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 21. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 22. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 23. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 24. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - High Grade
  • Table 25. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 26. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 27. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 28. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 29. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 30. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 31. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 32. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 33. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 34. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 35. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 36. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 37. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 38. Organic Developments Done By Companies
  • Table 39. Inorganic Developments Done By Companies
  • Table 40. Glossary of Terms, Asia Pacific glioma treatment market

List Of Figures

  • Figure 1. Asia Pacific Glioma Treatment Market Segmentation, By Country
  • Figure 2. Asia Pacific Glioma Treatment Market - Key Industry Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030
  • Figure 5. Asia Pacific Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
  • Figure 6. Astrocytoma: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Oligoastrocytoma: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Oligodendroglioma: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Asia Pacific Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
  • Figure 10. Surgery: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Chemotherapy: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Radiation Therapy: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Asia Pacific Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
  • Figure 15. Low Grade: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Grade I: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Grade II: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. High Grade: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Grade III: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Grade IV: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Asia Pacific Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 22. Hospital & Clinics: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Ambulatory Surgical Centers: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Asia Pacific Glioma Treatment Market, By Geography, 2022 ($Mn)
  • Figure 25. Asia Pacific Glioma Treatment Market, By Key Countries, 2022 And 2030 (%)
  • Figure 26. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 27. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 29. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 30. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 32. Growth Strategies Done by the Companies in the Market, (%)
目次
Product Code: BMIRE00029266

The Asia Pacific glioma treatment market is expected to grow from US$ 754.97 million in 2022 to US$ 1,538.88 million by 2030. It is estimated to grow at a CAGR of 9.3% from 2022 to 2030.

Increasing Opportunities in Emerging Economies Fuels Asia Pacific Glioma Treatment Market

Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies in the world. The healthcare sectors in these countries, as well as other developing economies, are projected to expand rapidly in the coming years. The expected growth is ascribed to changes in customer demand, an increase in awareness about healthcare services, and a continuous rise in the aging population. The global brain cancer diagnostics market is likely to grow significantly in the coming years with the proliferation of the healthcare sector. Further, increased government spending on healthcare facilities and consumer purchasing power contribute to the growth of the healthcare sector in developing countries.

Asian countries are witnessing continuous growth in their scientific capabilities, owing to the ongoing clinical research studies, centralized healthcare institutions, well-qualified and highly motivated workforces, and excellent clinical trial facilities. Further, many countries in Asia Pacific have a large and diverse patient pool, with ~60% of the global population residing in the region. Treatment guidelines prepared by regulatory bodies in the US and EU are followed in Asia Pacific for treating diseases, which offers solid prospects for significant and rapid patient recruitment. Thus, the growing healthcare sector in developing countries in Asia Pacific creates better opportunities for the Asia Pacific glioma treatment market players to expand their business.

Asia Pacific Glioma Treatment Market Overview

The Asia Pacific glioma treatment market in Asia Pacific is expected to grow at the fastest CAGR during the forecast period; China, India, and Japan are three major contributors to the market growth in this region. The market is mainly driven by increasing investments by the government and private sectors of the respective countries. A rise in collaborations among Asian countries and Western countries for the development of treatment, increasing demand for brain cancer treatments, and rising prevalence of brain tumors are a few of the key factors that are likely to drive the Asia Pacific glioma treatment market in this region during the forecast period.

China is a country with a vast population and has flourished healthcare infrastructure. The extent of social and economic development differs between the coastal area and rural areas. In the coastal regions, healthcare resources are relatively well developed and readily available compared to the rural areas in the west. Like any other developed and developing country, Japan also focuses on strengthening its healthcare system and providing better access to health systems to its citizens. The government is encouraging advancements in genomic testing through various programs and institutes. Moreover, the increasing geriatric population and the surging prevalence of brain tumors are expected to contribute to the development of the Asia Pacific glioma treatment market.

Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Glioma Treatment Market Segmentation

The Asia Pacific glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the Asia Pacific glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the Asia Pacific glioma treatment market in 2022.

Based on treatment type, the Asia Pacific glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the Asia Pacific glioma treatment market in 2022.

Based on grade, the Asia Pacific glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the Asia Pacific glioma treatment market in 2022.

Based on end user, the Asia Pacific glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the Asia Pacific glioma treatment market in 2022.

Based on country, the Asia Pacific glioma treatment market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific glioma treatment market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Glioma Treatment Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Government Funding for Glioma Treatment
    • 4.1.2 Increase in Prevalence of High-Grade Glioma
  • 4.2 Key Market Restraints
    • 4.2.1 High Cost of Diagnosis
  • 4.3 Key Market Opportunities
    • 4.3.1 Advancements in Healthcare Sector in Emerging Economies
  • 4.4 Future Trends
    • 4.4.1 Surge in Drug Approvals for Glioma Treatment
  • 4.5 Impact Analysis:

5. Glioma Treatment Market - Asia Pacific Market Analysis

  • 5.1 Asia Pacific Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

  • 6.1 Overview
  • 6.2 Asia Pacific Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
  • 6.3 Astrocytoma
    • 6.3.1 Overview
    • 6.3.2 Astrocytoma: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Oligoastrocytoma
    • 6.4.1 Overview
    • 6.4.2 Oligoastrocytoma: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Oligodendroglioma
    • 6.5.1 Overview
    • 6.5.2 Oligodendroglioma: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

  • 7.1 Overview
  • 7.2 Asia Pacific Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
  • 7.3 Surgery
    • 7.3.1 Overview
    • 7.3.2 Surgery: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Chemotherapy
    • 7.4.1 Overview
    • 7.4.2 Chemotherapy: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Radiation Therapy
    • 7.5.1 Overview
    • 7.5.2 Radiation Therapy: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

  • 8.1 Overview
  • 8.2 Asia Pacific Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
  • 8.3 Low Grade
    • 8.3.1 Overview
    • 8.3.2 Low Grade: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.3.2.1 Grade I: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.3.2.2 Grade II: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 High Grade
    • 8.4.1 Overview
    • 8.4.2 High Grade: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.4.2.1 Grade III: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.4.2.2 Grade IV: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 Asia Pacific Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.3 Hospital & Clinics
    • 9.3.1 Overview
    • 9.3.2 Hospital & Clinics: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Ambulatory Surgical Centers
    • 9.4.1 Overview
    • 9.4.2 Ambulatory Surgical Centers: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Glioma Treatment Market - Country Analysis

  • 10.1 Overview
    • 10.1.1 Asia Pacific Glioma Treatment Market, by Country
      • 10.1.1.1 China
        • 10.1.1.1.1 China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.1.2 China: Asia Pacific Glioma Treatment Market, by Disease
        • 10.1.1.1.3 China: Asia Pacific Glioma Treatment Market, by Treatment Type
        • 10.1.1.1.4 China: Asia Pacific Glioma Treatment Market, by Grade
        • 10.1.1.1.4.1 China: Asia Pacific Glioma Treatment Market, by Low Grade
        • 10.1.1.1.4.2 China: Asia Pacific Glioma Treatment Market, by High Grade
        • 10.1.1.1.5 China: Asia Pacific Glioma Treatment Market, by End User
      • 10.1.1.2 Japan
        • 10.1.1.2.1 Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.2.2 Japan: Asia Pacific Glioma Treatment Market, by Disease
        • 10.1.1.2.3 Japan: Asia Pacific Glioma Treatment Market, by Treatment Type
        • 10.1.1.2.4 Japan: Asia Pacific Glioma Treatment Market, by Grade
        • 10.1.1.2.4.1 Japan: Asia Pacific Glioma Treatment Market, by Low Grade
        • 10.1.1.2.4.2 Japan: Asia Pacific Glioma Treatment Market, by High Grade
        • 10.1.1.2.5 Japan: Asia Pacific Glioma Treatment Market, by End User
      • 10.1.1.3 India
        • 10.1.1.3.1 India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.3.2 India: Asia Pacific Glioma Treatment Market, by Disease
        • 10.1.1.3.3 India: Asia Pacific Glioma Treatment Market, by Treatment Type
        • 10.1.1.3.4 India: Asia Pacific Glioma Treatment Market, by Grade
        • 10.1.1.3.4.1 India: Asia Pacific Glioma Treatment Market, by Low Grade
        • 10.1.1.3.4.2 India: Asia Pacific Glioma Treatment Market, by High Grade
        • 10.1.1.3.5 India: Asia Pacific Glioma Treatment Market, by End User
      • 10.1.1.4 South Korea
        • 10.1.1.4.1 South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.4.2 South Korea: Asia Pacific Glioma Treatment Market, by Disease
        • 10.1.1.4.3 South Korea: Asia Pacific Glioma Treatment Market, by Treatment Type
        • 10.1.1.4.4 South Korea: Asia Pacific Glioma Treatment Market, by Grade
        • 10.1.1.4.4.1 South Korea: Asia Pacific Glioma Treatment Market, by Low Grade
        • 10.1.1.4.4.2 South Korea: Asia Pacific Glioma Treatment Market, by High Grade
        • 10.1.1.4.5 South Korea: Asia Pacific Glioma Treatment Market, by End User
      • 10.1.1.5 Australia
        • 10.1.1.5.1 Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.5.2 Australia: Asia Pacific Glioma Treatment Market, by Disease
        • 10.1.1.5.3 Australia: Asia Pacific Glioma Treatment Market, by Treatment Type
        • 10.1.1.5.4 Australia: Asia Pacific Glioma Treatment Market, by Grade
        • 10.1.1.5.4.1 Australia: Asia Pacific Glioma Treatment Market, by Low Grade
        • 10.1.1.5.4.2 Australia: Asia Pacific Glioma Treatment Market, by High Grade
        • 10.1.1.5.5 Australia: Asia Pacific Glioma Treatment Market, by End User
      • 10.1.1.6 Rest of Asia Pacific
        • 10.1.1.6.1 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Disease
        • 10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Treatment Type
        • 10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Grade
        • 10.1.1.6.4.1 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Low Grade
        • 10.1.1.6.4.2 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by High Grade
        • 10.1.1.6.5 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by End User

11. Asia Pacific Glioma Treatment Market Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies Done by the Companies in the Market, (%)
  • 11.3 Organic Developments
    • 11.3.1 Overview
  • 11.4 Inorganic Developments
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 F. Hoffmann-La Roche Ltd
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Merck & Co Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Sun Pharmaceutical Industries Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Amgen Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Teva Pharmaceutical Industries Ltd
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Pfizer Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Amneal Pharmaceuticals Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Biocon Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms